Company Analysis
Sign in

Xencor, Inc. (XNCR)

Nasdaq: XNCR · Pharmaceutical Preparations · Pasadena, CA · filing with the SEC since 2005
Full chart Alerts Compare
Grade5.1
◀ Past 4.3● Present 6.1▶ Future 4.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

222 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Xencor, Inc.’s names, not what it holds today.

Patents granted
222
222 utility, 1976 to Dec 31, 2025
Granted in 2025
17
Against 15 in 2024 and 15 in 2023
Applications published
416
26 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology63
Pharmaceuticals16
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Xencor, Inc. its own name
US, as the owner printed on each patent. 2 more under the same name are not counted (printed in CA, printed in LR)
222 granted
210 published
Xencor, Inc. its own name
named as the applicant on its applications, in US
0 granted
206 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,518Methods and compositions for inhibiting CD32B expressing cells in IgG4-related diseasesPharmaceuticalsXencor, Inc.
Dec 30, 202512,509,495LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and LAG-3 antigen binding domainsBiotechnologyXencor, Inc.
Dec 16, 202512,497,457Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseasesPharmaceuticalsXencor, Inc.
Dec 9, 202512,492,253Anti-human C5 antibodiesBiotechnologyXencor, Inc.
Dec 2, 202512,486,311CTLA4-Ig immunoadhesinsPharmaceuticalsXencor, Inc.
Nov 11, 202512,466,897Heterodimeric human IgG1 polypeptides with isoelectric point modificationsBiotechnologyXencor, Inc.
Oct 21, 202512,448,423Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domainsBiotechnologyXencor, Inc.
Sep 16, 202512,415,849Heterodimeric proteinsBiotechnologyXencor, Inc.
Sep 2, 202512,404,329Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3BiotechnologyXencor, Inc.
Aug 26, 202512,398,207Heterodimeric antibodies that bind CD3 and CLDN6BiotechnologyXencor, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388704ANTI-CD28 X ANTI-PSMA ANTIBODIESBiotechnologyXencor, Inc.
Dec 25, 20252025/0388691METHODS FOR TREATING LYMPHOMABiotechnologyXencor, Inc.
Nov 27, 20252025/0361311ANTI-TNF-LIKE LIGAND 1A (TL1A) ANTIBODIESPharmaceuticalsXencor, Inc.
Nov 6, 20252025/0340650METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASESPharmaceuticalsXencor, Inc.
Oct 30, 20252025/0333519BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIESBiotechnologyXencor, Inc.
Oct 2, 20252025/0304724HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENSBiotechnologyXencor, Inc.
Oct 2, 20252025/0304667COMPLEMENT COMPONENT C5 ANTIBODIESPharmaceuticalsXencor, Inc.
Jul 31, 20252025/0243279BISPECIFIC ANTIBODIES THAT BIND TO NKP46 AND MICA/BBiotechnologyXencor, Inc.
Jul 17, 20252025/0230262HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONSBiotechnologyXencor, Inc. · patent 12,466,897 granted from it
Jul 17, 20252025/0230227Fc VARIANTS WITH ALTERED BINDING TO FcRnBiotechnologyXencor, Inc.
What it applied for, 2024 to 2025: Biotechnology 41 · Pharmaceuticals 12.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton XNCR · research, not advice